Objective
Nearly all aspects of cell life (and death) are controlled by protein phosphorylation catalysed by protein kinases (PKs). PKs belong to the largest single family of enzymes, numbering over 500 and accouting for almost 2% of the proteins encoded by the human genome. Recent success in drug discovery (e.g. Imatinib, GlivecR) demonstrate that PKs are excellent drug targets. The Pro-KinaseResearch consortium will combine European expertise on basic research on PKs and that on rational drug discovery, in order to develop new drug candidates and treatment strategies for major diseases like cancer, autoimmune disorders, vascular diseases and degenerative brain diseases. Thus, the aim of this IP is to study PKs as drug targets for more effective and better tolerated drug therapies meeting the needs of ageing population.
The joint effort will focus on the biochemical properties and structure function relationships of a wide variety of PKs having the potential as pharmacological targets. We will evaluate the regulatory domains, catalytic domains and also anchoring proteins of various PKs, as drug targets. Natural compounds from European biosphere, e.g. Cyanobacteria, and compounds from combinatorial chemistry, chemical libraries, affecting activity of PKs will be analysed to gain knowledge of their structure/activity relationship. These compounds will be used as model drugs or templates for a rational drug design where new compounds will be modelled and synthesised. This consortium has a broad range of bioactivity assays to study the efficacy and toxicity of the new compounds. The consortium includes academic groups with unique expertise in biochemistry, structural crystallography, synthetic organic chemistry, lead structure optimisation and other fields of rational drug discovery; clinically oriented groups with proven experience in animal models and phase I-II clinical studies under GCP guidelines; and SME partners to assure a quick transfer of knowledge.
Fields of science
Not validated
Not validated
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineangiologyvascular diseases
- natural scienceschemical sciencesorganic chemistry
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health sciencesclinical medicineoncology
Call for proposal
FP6-2002-LIFESCIHEALTH
See other projects for this call
Funding Scheme
IP - Integrated ProjectCoordinator
UNIVERSITY OF HELSINKI
Finland
See on map
Participants (27)
LAUSANNE
See on map
DUNDEE
See on map
DEBRECEN
See on map
INNSBRUCK
See on map
ZURICH
See on map
OXFORD
See on map
PARIS
See on map
PADOVA
See on map
LONDON
See on map
JERUSALEM
See on map
PARIS
See on map
MUNICH
See on map
BERGEN
See on map
BIRMINGHAM
See on map
FREIBURG
See on map
UNTERHACHING
See on map
MARSEILLES
See on map
MARIA ENZERSDORF
See on map
2098 LELYSTAD
See on map
BRAUNSCHWEIG
See on map
INNSBRUCK
See on map
2098 LELYSTAD
See on map
GENEVE 4
See on map
MILANO
See on map
VIENNA
See on map
MOSCOW
See on map
MOSCOW
See on map